Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

unknown267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
unknown

Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain.

NCT04711811
unknown

Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.

NCT04604288
terminatedphase_2

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

NCT04362189

Clinical Trials (3)

Showing 3 of 3 trials
NCT04711811

Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain.

Unknown
NCT04604288

Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.

Unknown
NCT04362189Phase 2

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

Terminated

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3